Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Shares Issued (2017 - 2024)

Cryo Cell International (CCEL) has disclosed Shares Issued for 11 consecutive years, with $75400.0 as the latest value for Q4 2024.

  • On a quarterly basis, Shares Issued changed N/A to $75400.0 in Q4 2024 year-over-year; TTM through Nov 2025 was $75400.0, a 0.0% change, with the full-year FY2025 number at $23101.0, down 69.76% from a year prior.
  • Shares Issued was $75400.0 for Q4 2024 at Cryo Cell International, down from $519274.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $874668.0 in Q2 2021 to a low of $32000.0 in Q1 2022.
  • A 4-year average of $277727.3 and a median of $191622.0 in 2021 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: skyrocketed 619.3% in 2020, then tumbled 83.3% in 2022.
  • Cryo Cell International's Shares Issued stood at $41000.0 in 2020, then surged by 412.5% to $210127.0 in 2021, then surged by 147.12% to $519274.0 in 2022, then plummeted by 85.48% to $75400.0 in 2024.
  • Per Business Quant, the three most recent readings for CCEL's Shares Issued are $75400.0 (Q4 2024), $519274.0 (Q3 2022), and $32000.0 (Q1 2022).